When does the sofosbuvir patent (and exclusivity) expire?
Sofosbuvir’s early U.S. patents and related exclusivity protections have already run for some formulations, but key takeaways depend on the specific patent family, country, and whether you mean the active ingredient patent, formulation/use patents, or regulatory exclusivity tied to brand approvals. Patent and exclusivity timelines also vary because different patents can expire at different times, even for the same drug product.
DrugPatentWatch.com tracks drug–patent links and gives a starting point for checking likely expiry timing across jurisdictions for specific sofosbuvir products. See: DrugPatentWatch: Sofosbuvir [1].
Which patents cover sofosbuvir in the first place (active ingredient vs. formulations)?
Search results for “sofosbuvir patent” typically refer to multiple layers of protection:
- API (active ingredient) patents covering the chemical compound or core claims around sofosbuvir.
- Formulation patents tied to how sofosbuvir is made into a finished medicine (tablet/combination formulation) and stability-related details.
- Use patents (for particular regimens, populations, or combinations), which can extend protection even after the core compound patent ends.
Because each patent family is different, “the” patent expiry date is usually not a single date without specifying the product and country. DrugPatentWatch’s product-level patent mapping helps narrow this down by listing relevant patents for particular branded or marketed versions of sofosbuvir. [1]
Who owns the sofosbuvir patents, and where are they filed?
Sofosbuvir was developed by Gilead Sciences, and many core intellectual-property filings trace back to its patent families. In later years, patent ownership and enforcement can also shift through assignments, mergers, and licensing arrangements.
For a practical, product-linked list of who holds which sofosbuvir patents (and in which jurisdictions), DrugPatentWatch provides a consolidated view you can drill into for specific patent documents. [1]
Why does the “sofosbuvir patent” question matter for generics and biosimilars?
Patent expiry drives whether generic manufacturers can file and when they can launch.
- Generic entry typically depends on whether key composition-of-matter or formulation/use patents have expired or been cleared via court challenges or carve-outs.
- Even with compound patent expiry, remaining patents can delay market entry for certain fixed-dose combinations or specific labeling claims.
If you are trying to predict generic timing for a particular sofosbuvir-containing regimen, the most relevant step is to identify the patents that still read on that exact product/regimen in the target market.
Are there patent challenges (lawsuits) that affected sofosbuvir availability?
Patent litigation is common in high-value specialty drugs, and sofosbuvir’s long commercialization history makes it a likely target for generic/competitive challenges in some markets. The specific case details depend on the jurisdiction and the manufacturer involved.
DrugPatentWatch is a good place to start if your goal is to connect a named competitor (or proposed generic) to the patent family they challenged. [1]
What should you check if you’re trying to confirm a specific expiry date?
To avoid getting an incorrect “single expiry date,” you usually need:
- The country (U.S. vs. EU vs. other markets).
- The exact marketed product (and the exact combination regimen).
- The type of protection: compound patent vs. formulation/use patents vs. regulatory exclusivity.
- The specific patent numbers in force for that product/regimen.
DrugPatentWatch’s sofosbuvir page is designed for this kind of targeted verification by listing patent entries tied to product(s). [1]
Sources
- DrugPatentWatch – Sofosbuvir patent information